Market Overview

UPDATE: Citigroup Raises Eli Lilly PT to $60 on Eli Lilly on Potential Upside

Share:
Related LLY
Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell
The Difference Between Shareholders And Stakeholders
Early Data For Next Generation Of Imbruvica's Challengers (Seeking Alpha)

Citigroup maintained Eli Lilly and Company (NYSE: LLY) with a Buy rating and raised the price target from $55.00 to $60.00.

Citigroup noted, "Lilly's base business is performing ahead of our expectations (Alimta, Elanco, Diabetes and Emerging markets). Consequently, we continue to see upside for Lilly due to the asymmetric risk reward given the minimal value being discounted for the key pipeline agent ramucirumab (cancer). Buy-rated Pfizer, Lilly and Forest remain our favoured names in US pharma."

Eli Lilly closed at $54.32 on Tuesday.

Latest Ratings for LLY

DateFirmActionFromTo
Nov 2016Atlantic EquitiesDowngradesOverweightNeutral
Nov 2016BMO CapitalDowngradesOutperformMarket Perform
Sep 2016Goldman SachsUpgradesNeutralBuy

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

View Comments and Join the Discussion!